Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372196 | 0.84 | MAP3K12 (0.41) | MAP3K12MAPK14FDPSTRPV4AURKA | |
| SCHEMBL30999000 | 0.80 | FDPS (0.41) | MAP3K12MAPK14FDPSAURKARPS6KB1 | |
| SCHEMBL7232240 | 0.80 | AR (0.55) | MAPK14JAK2JAK3 | |
| SCHEMBL3141770 | 0.79 | CDC7 (0.46) | MAP3K12ABCB1ABCG2TRPV4CLK4 | |
| SCHEMBL17700214 | 0.77 | HRH4 (0.52) | MAP3K12MAPK14HRH4TRPV4 | |
| SCHEMBL30998998 | 0.77 | FDPS (0.39) | MAP3K12FDPSAURKARPS6KB1PANK3 | |
| SCHEMBL29851369 | 0.75 | FDPS (0.59) | MAPK14MAPK10HRH4FDPSTRPM8 | |
| SCHEMBL828257 | 0.75 | FDPS (0.59) | MAPK14MAPK10HRH4FDPSTRPM8 | |
| SCHEMBL30397432 | 0.75 | KDM4E (0.47) | MAP3K12TRPV4CLK4JAK2 | |
| SCHEMBL3600453 | 0.75 | KDM4E (0.47) | MAP3K12TRPV4CLK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| WO-2022136914-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-06-30 | — | — | WO | disclosed |
| US-10428044-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| US-10428044-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| EP-3157914-B1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma AG (DE) | 2018-09-26 | — | — | EP | disclosed |
| EP-3157914-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma Aktiengesellschaft (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-20170101391-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101391-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101391-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | US | disclosed |
| WO-2015193339-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193339-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9012656-B2 | Oligothiophene derivate as molecular probes | CELLUMINOVA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| WO-2010117662-A1 | MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117662-A1 | MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101391-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BUB1, BUB1B, AURKB | MAP3K12 204/4885ABCB1 1310/4885ABCC1 2008/4885 |
| US-10428044-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | BUB1, BUB1B, AURKB | MAP3K12 204/4885ABCB1 1310/4885ABCC1 2008/4885 |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | MAP3K12 91/4885ABCB1 4410/4885ABCC1 3278/4885 |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | PRKCQ, PRKCA, PRKCZ | MAP3K12 47/4885ABCB1 3788/4885ABCC1 2984/4885 |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | S1PR5, S1PR1, S1PR2 | MAP3K12 2028/4885ABCB1 2144/4885ABCC1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.